HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Philip Graham Selected Research

1-(5-hydroxyhexyl)-3,7-dimethylxanthine

7/2016A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
1/2013A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Philip Graham Research Topics

Disease

1Hot Flashes
12/2020
1Chronic Renal Insufficiency
07/2016
1Diabetic Nephropathies (Diabetic Nephropathy)
01/2013
1Thrombosis (Thrombus)
03/2012

Drug/Important Bio-Agent (IBA)

2Pharmaceutical PreparationsIBA
07/2016 - 01/2013
21-(5-hydroxyhexyl)-3,7-dimethylxanthineIBA
07/2016 - 01/2013
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
12/2020
1DeuteriumIBA
01/2013
1FibrinIBA
03/2012
1Serum AlbuminIBA
03/2012
1Fibrinogen (Factor I)FDA Link
03/2012
1Peptides (Polypeptides)IBA
03/2012